Afrezza, an inhaled insulin approved by the US FDA in 2014, when combined with long-acting basal analog insulin, has shown to be a non-inferior treatment option for those with type 1 diabetes. A recent study presented at the American Diabetes Association 84th Scientific Sessions compared Afrezza with usual care in 123 adults with type 1 diabetes. While both groups had similar A1c levels at 17 weeks, more patients on Afrezza achieved A1c levels below 7%. Proper dosing and frequent administration of Afrezza are crucial for optimal outcomes, as higher doses may be needed compared to injected insulin. Some participants preferred Afrezza over traditional insulin therapy due to its quick onset and ease of use.
Source link
Inhaled Insulin Plus Degludec an Option for Type 1 Diabetes
